Mizgala H F
Faculty of Medicine, University of British Columbia, Vancouver.
Can Anaesth Soc J. 1983 May;30(3 Pt 2):S5-10. doi: 10.1007/BF03009971.
The calcium channel blockers provide an exciting and effective new therapeutic tool in the management of ischaemic cardiac syndromes and may prove popular and effective in the treatment of a variety of other disorders. They have provided a new approach to treatment and have added new insights into the pathogenesis of ischaemic cardiac syndromes. Their introduction into clinical practice has been swift and many of our concepts regarding their pharmacologic activities in man remain based on theoretic considerations. Their expanding clinical use and further comparative studies will undoubtedly provide further information in regard to indications, adverse effects, drug interaction and long-term safety. Particular caution is advised when they are combined with certain antiarrhythmic agents, digitalis and particularly beta adrenergic blocking agents. Little is known about their interaction with various general anaesthetic agents and for this reason particular vigilance is required as more patients receiving these agents are admitted for surgical procedures.
钙通道阻滞剂为缺血性心脏综合征的治疗提供了一种令人振奋且有效的新治疗手段,并且在治疗多种其他疾病方面可能会被证明既受欢迎又有效。它们为治疗提供了一种新方法,并为缺血性心脏综合征的发病机制增添了新的见解。它们迅速被引入临床实践,而我们许多关于其在人体药理活性的概念仍基于理论考量。其临床应用的不断扩展以及进一步的对比研究无疑将提供有关适应证、不良反应、药物相互作用和长期安全性的更多信息。当它们与某些抗心律失常药物、洋地黄尤其是β肾上腺素能阻滞剂合用时,建议格外谨慎。对于它们与各种全身麻醉剂的相互作用知之甚少,因此,由于越来越多接受这些药物的患者需要接受外科手术,所以需要格外警惕。